Barclays analyst Luke Sergott downgraded Revvity (RVTY) to Equal Weight from Overweight with a price target of $95, down from $118. The firm sees margin risk heading into the company’s Q1 report as well as potential competitive threats to flow cytometry reagents from Waters. Flow reagents are a small portion of Revvity’s overall revenues, but instrumental in the company hitting its growth targets, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity unveils Signals BioDesign offering
- Revvity price target lowered to $108 from $118 at Evercore ISI
- Revvity price target lowered to $96 from $105 at JPMorgan
- Revvity upgraded to Hold from Sell at Nephron Research
- Revvity’s AI Push Brings Innovation Potential but Heightened Operational, Legal, and Reputational Risks